Cancer Genetics, Inc. (CGI) takes a personalized approach to diagnosing leukemia. The company developed a DNA-based genomic test to identify chronic lymphocytic leukemia in patients. Called MatBA-CLL, the microarray test can improve the diagnosis, prognosis, and response to treatment. CGI's lab in New Jersey caters to area hospitals, cancer centers, reference laboratories, and doctors' offices. It also has a pipeline of other genomic tests for hematological, urogenital (kidney, prostate and bladder cancer), and HPV-associated cancers that are complicated to predict. CGI was founded in 1999 by Chairman Dr. Raju Chaganti. The company filed a $50 million initial public offering in late 2011.